Elucida Oncology Taps Geno J. Germano, Veteran Pfizer Executive and Former Intrexon President, as New CEO
NEW YORK, NY -- ELUCIDA ONCOLOGY, INC®, a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Geno J. Germano as its President and CEO. Mr. Germano is a 30-year veteran of the pharmaceutical industry and was most recently President of Intrexon, a leader in synthetic biology.
This move comes as Elucida is ramping up clinical trials for its innovative C-Dot platform and technology. Several clinical trials are currently underway at the Memorial Sloan Kettering Cancer Center, testing the promise of C-Dot technology – the base particle originally developed at Cornell University – for mapping several tumors, including melanoma, breast, prostate, and malignant brain tumor patients. Several C-Dot therapies, encompassing small molecule drug conjugates and targeted radiotherapies, have also been synthesized and tested in animal models with the aim of eventually achieving improved therapeutic outcomes in patients.
Mr. Germano has held several high-level leadership roles at some of the industry’s biggest and most innovative companies, including Pfizer, Johnson & Johnson, and Wyeth. Mr. Germano led Pfizer’s Global Innovative Pharma Business, cultivating a $14 billion operation and guiding the development of an extensive portfolio of products in the cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare disease areas. Previously, Mr. Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units and directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses.
Mr. Germano is heavily involved in all aspects of the pharmaceutical industry. He serves on the Advisory Board of the Healthcare Businesswomen’s Association and is a Trustee of the Albany College of Pharmacy, where he received his Bachelor of Science degree. He is currently a Director of Sage Therapeutics and of The Medicines Company. and formerly served as a Director of Bioverativ and Zoetis.
Robert Essner, Executive Chairman of Elucida Oncology, commented “Geno’s considerable experience in the pharmaceutical industry makes him an invaluable addition to the Elucida team. The background and stature he brings to this pivotal role will, without question, help our company fulfil its goal of becoming a leader in the world of precision medicine oncology.”
“I am thrilled to be joining Elucida Oncology at this critical moment in the company’s history, as it accelerates clinical trials with an eye on improving patient outcome,” said Mr. Germano. “My career is predicated on a commitment to meaningful change and Elucida affords the opportunity to explore the world of precision oncology and, perhaps, push the boundaries of its diagnostic and therapeutic applications. I am excited to join this dynamic team.”
About Elucida Oncology
Elucida Oncology, Inc., is a privately held, clinical-stage biotechnology company focused on developing and commercializing a first-in-class ultra-small nanoparticle platform for the diagnosis, visualization and treatment of primary solid tumor and metastatic cancers. The novel Target or Clear™ characteristic of the C-Dot product platform is demonstrating the combination of advanced cancer cell targeting combined with the potential safety advance afforded by bulk clearance through the renal system.
For more information on Elucida Oncology, Inc., please visit www.elucidaoncology.com.
Released August 22, 2018